Q32 Bio and Homology Medicines Announce Merger Agreement

--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart in Phase 2 for the treatment of atopic dermatitis and...

Related Keywords

Massachusetts ,United States ,Bedford ,Waltham ,Maria Marzilli ,Saul Fink ,Oxford Biomedica ,Brendan Burns ,Albert Seymour ,David Appugliese ,Shelia Violette ,Piper Sandler ,Jodie Morrison ,Brad Smith ,Sarah Sutton ,Jason Campagna ,Nasdaq ,Exchange Commission ,Corporate Strategy Program Operations ,Bristol Myers Squibb ,Oxford Biomedica Solutions ,Homology Medicines Inc ,Amgen ,Latham Watkins ,Bio Inc ,Cu Healthcare Innovation Fund ,Osage University Partners ,Atlas Venture ,Oxford Solutions ,Goodwin Procter ,Homology Medicines ,Acorn Bioventures ,Innovation Fund ,Sanofi Ventures ,Agent Capital ,Chief Executive Officer ,Associated Vasculitis ,Homology Medicine ,Current Report ,Leerink Partners ,Chief Executive ,Chief Scientific ,Chief Medical ,Chief Technology ,Executive Vice President ,Corporate Strategy ,Senior Vice President ,Securities Litigation Reform Act ,Homology Medicine Form ,One Patriots Park ,Markets ,